In total, 20 out of 24 patients were evaluable for efficacy, with 15 patients at Stage IV (the most advanced stage of ovarian cancer), and the remainder were Stage III.
Preliminary analysis shows one complete response (no measurable disease after treatment) and two partial responses (tumour shrunk is size by at least 30%).
This means an overall response rate of 15% (three out of 20 patients) which compares favourably to a figure of 10% for historical controls.
“Extremely encouraging results”
Kazia chief executive officer Dr James Garner said: “Patient follow-up for this study is now complete, and we move into a period of finalising and analysing the data.
“Preliminary results are extremely encouraging."
The median progression-free survival (PFS) was 5.5 months, versus the historical control of 3.4 months.
Garner said: “For some patients in this very challenging patient population, Cantrixil has been able to shrink tumours and delay disease progression, demonstrating a clinically meaningful benefit.
“The outstanding success of the study reflects the enormous commitment and energy of all involved – clinicians, patients, contractors, and Kazia colleagues – and we are grateful for all their efforts.”
Growing body of data
Kazia is confident that the growing body of data provides strong evidence that Cantrixil is clinically active in this very late-stage patient population and can shrink tumours in a proportion of patients.
Australian lead investigator Associate Professor Jermaine Coward said: “Despite recent progress in ovarian cancer, there remains an urgent need for new therapies.
“The Cantrixil phase I study was conducted in a very late-stage patient population, with few effective treatment options.
“In that context, my colleagues and I consider the data to be extremely promising.”
Kazia will now work closely with sites and investigators to collect and validate all remaining data and expects to release final data in the second half of 2020.
Share purchase plan
On Wednesday, April 8, Kazia announced a share purchase plan for sector-specialist institutional investors in Australia and internationally at A40 cents per share to raise around A$7.2 million.
The placement was led by high-quality new and existing institutional investors encouraged by strongly positive emerging data from a paxalisib phase II clinical trial in glioblastoma.
A share purchase plan has also been launched to allow eligible existing shareholders the opportunity to acquire new shares at the same price as the placement and to raise up to A$2 million.
This booklet is being distributed to eligible shareholders today and the plan opens on Monday, April 20.